FDA
-
-
-
-
-
-
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
-
-
-
-
-
-
-
Chiesi and Protalix seek EMA re-examination for Elfabrio dosing regimen
-
-
-
-
-
-
-
Protalix BioTherapeutics names Gilad Mamlok as new CFO
-
-
-
-
-
-
-
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
-
-
-
-
-
-
-
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
-
-
-
-
-
-
-
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results
-
-
-
-
-
-
-
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024
-
322,248 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

